SWM
ORMP icon

SeaCrest Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

SeaCrest Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,500
Closed -$5K – 1438
2019
Q1 		$5K Buy
+1,500
New +$4.96K ﹤0.01% 1726

Other funds holding ORMP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
RPC
Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return

SeaCrest Wealth Management's ORMP Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2019, closing a stake of 1,500 shares — an estimated $5K sold.

SeaCrest Wealth Management first reported a position in ORMP in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 26 funds tracked by Wall St. Rank hold ORMP as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Oramed Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,500 Oramed Pharmaceuticals shares in Q2 2019, an estimated $5K.
  • SeaCrest Wealth Management first reported a position in Oramed Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • SeaCrest Wealth Management's Oramed Pharmaceuticals position peaked at $5K in Q1 2019.
  • 26 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.